Compare C3.ai Inc (AI) vs Biogen Inc (BIIB) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
C3.ai Inc vs Biogen Inc — how do they compare? C3.ai Inc trades at $8.87 (market cap $1.39B), while Biogen Inc trades at $201.47 (market cap $30.37B). The key difference: Biogen Inc is far larger — about 21.8× C3.ai Inc's market cap, and Biogen Inc is trading nearer its 52-week high, C3.ai Inc nearer its low. Which is the better fit depends on your goals.
| AI | BIIB | |
|---|---|---|
Market Cap | $1.39B | $30.37B |
Sector | Technology | Health |
52-Week High | $29.16 | $216.63 |
52-Week Low | $7.76 | $122.68 |
Enterprise Value | $818.29M | $32.65B |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About C3.ai Inc
C3.ai Inc is an enterprise artificial intelligence company. The company provides software-as-a-service applications that enable customers to rapidly develop, deploy, and operate large-scale Enterprise AI applications across any infrastructure. It provides solutions under three divisions namely, The C3 AI Suite, is a comprehensive application development and runtime environment that is designed to allow customers to rapidly design, develop, and deploy Enterprise AI applications of any type
Read more on AI →About Biogen Inc
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021.
Read more on BIIB →
